Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GNPS_GC_Low res QqQ WinCF study data_SPME

ABSTRACT: GC-MS data from: Longitudinal sputum VOC data from: Neutrophilic proteolysis in the cystic fibrosis lung correlates with a pathogenic microbiome RA Quinn, S Adem, RH Mills, W Comstock, LDR Goldasich, G Humphrey, ... RA Quinn, S Adem, RH Mills, W Comstock, LDR Goldasich, G Humphrey, ... Microbiome 7 (1), 23 The volatiles above sputum samples were sampled with SPME.

INSTRUMENT(S): Thermo Scientific TRACE 1310 GC-MS

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Pieter Dorrestein

PROVIDER: MSV000084348 | GNPS |

REPOSITORIES: GNPS

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Association of sputum microbiome with exacerbations, patient subgroups and host response in chronic obstructive pulmonary disease

Project description:Little is known about the lung microbiome dynamics and host-microbiome interactions in relation to chronic obstructive pulmonary disease (COPD) exacerbations and in patient subgroups based on smoking status and disease severity. Here we performed a 16S ribosomal RNA survey on sputum microbiome from 16 healthy and 43 COPD subjects. For COPD subjects, a longitudinal sampling was performed from stable state to exacerbations, at two and six weeks post-exacerbations and at six months from first stable visit. Host sputum transcriptome were characterized for a subset of COPD patient samples.

2021-03-21 | GSE112165 | GEO

Transcription profiling by array of Pseudomonas aeruginosa wild-type and phhR mutants grown in a defined synthetic cystic fibrosis sputum medium with and without aromatic amino acids

Project description:Arrays comparing Pseudomonas aeruginosa growth in a defined synthetic cystic fibrosis sputum medium with and without aromatic amino acids. Additional arrays comparing wild-type Pseudomonas aeruginosa and phhR mutant P. aeruginosa in defined synthetic cystic fibrosis sputum medium.

2010-04-01 | E-MEXP-2593 | biostudies-arrayexpress

Project description:Cystic Fibrosis Sputum Microbiome After Trikafta

| PRJNA733203 | ENA

Project description:Cystic Fibrosis Sputum and Saliva Microbiome

| PRJNA611611 | ENA

In vitro evolution of Pseudomonas aeruginosa AA2 biofilms in the presence of cystic fibrosis lung microbiome members

Project description:P. aeruginosa was cultured in a MultiScreen-Mesh plate, which has a filter at the bottom of the wells. The plate was immersed in either in medium alone (control) or in medium inoculated with a mixture of five bacterial strains commonly found in cystic fibrosis sputum (\"microbiome\"). The filter prevented physical contact between P. aeruginosa and the other bacteria, yet soluble products could migrate through the filter into the P. aeruginosa biofilm. P. aeruginosa was then allowed to form biofilms in the wells for 72h, then the biofilm was harvested and a fraction of the harvested cells were used for re-inoculations. This was repeated for 18 cycles for a total of 54 days.

2019-09-13 | E-MTAB-7331 | biostudies-arrayexpress

Project description:Cystic Fibrosis sputum longitudinal metagenomic and Pseudomonas aeruginosa population analysis

| PRJNA450593 | ENA

GNPS 3D WinCF Tubes

Project description:A collection of cultured microbial communities from cystic fibrosis sputum samples sectioned through an oxygen gradient and treated with antibiotics.

2016-12-14 | MSV000080397 | GNPS

Transcription profiling of Burkholderia cepacia grown in cystic fibrosis sputum

Project description:Transcriptome profile of B. cenocepacia grown in cystic fibrosis sputum

2008-01-01 | E-MEXP-1261 | biostudies-arrayexpress

Morphine treatment leads to temporal modulation of the gut microbiome

Project description:Opioid analgesics are frequently prescribed in the United States and worldwide. However, serious side effects such as addiction, immunosuppression and gastrointestinal symptoms limit long term use. In the current study using a chronic morphine-murine model a longitudinal approach was undertaken to investigate the role of morphine modulation of gut microbiome as a mechanism contributing to the negative consequences associated with opioids use. The results revealed a significant shift in the gut microbiome and metabolome within 24 hours following morphine treatment when compared to placebo. Morphine induced gut microbial dysbiosis exhibited distinct characteristic signatures profiles including significant increase in communities associated with pathogenic function, decrease in communities associated with stress tolerance. Collectively, these results reveal opioids-induced distinct alteration of gut microbiome, may contribute to opioids-induced pathogenesis. Therapeutics directed at these targets may prolong the efficacy long term opioid use with fewer side effects.

2018-04-16 | E-MTAB-5550 | biostudies-arrayexpress

Comparison of the inflammatory niches of CF and COPD and the differences to healthy controls

Project description:This study aimed to compare – at a multi-omics level, inflammation, protease abundance and activity, microbiome, and proteome in sputum samples from patients with cystic fibrosis (CF, n=38) or chronic obstructive pulmonary disease (COPD, n=18) and healthy controls (n=10) to identify shared and unique pathways between these respiratory conditions. Sputum analysis revealed elevated inflammatory cell counts in both CF and COPD patients, with neutrophils being the dominant cell type. Key inflammatory markers, including IL-1β, TNF-α, TGF-β1, IL-8, and LTB4, were increased in both disease groups, with the highest levels observed in CF. Conversely, COPD patients exhibited higher levels of IL-5, IL-6, and IL-10. Microbiome analysis showed distinct clusters for each group, with CF patients often characterized by a preponderance of Pseudomonas. Hierarchical clustering unveiled robust interdependencies between microbiome parameters and inflammation, a richer and more diverse microbiome was associated with a healthier microbial community. This study uncovered significant disparities in inflammation, microbiome composition, and proteome profiles among CF, COPD, and healthy control cohorts. Neutrophilic inflammation and protease activity emerged as common factors in both diseases highlighting proteases as good targets for both indications, while distinct microbial signatures were identified. These findings offer valuable insights into the underlying mechanisms of CF and COPD and may inform future clinical strategies.

2025-09-08 | PXD048388 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data